Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain;Gammaglobulina subcutánea en inmunodeficiencia común variable. Primera experiencia en España

Anales de Pediatria

Volumn 70, Issue 2, 2009, Pages 111-119

  Maroto Hernando, M ^a   Soler Palacin P ^a   Martin Nalda A ^a   Oliveras Arenas, M ^a   Espanol Boren T ^a   Figueras Nadal, C ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Common variable immunodeficiency; Immunoglobulin; Pharmacoeconomic evaluation; Quality of life; Subcutaneous injection

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; COST EFFECTIVENESS ANALYSIS; DESCRIPTIVE RESEARCH; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; FEVER; HEMATOMA; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RATE; INJECTION SITE INDURATION; INJECTION SITE REACTION; MALE; OBSERVATIONAL STUDY; PAIN; QUALITY OF LIFE; SPAIN; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; CHILD; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; GAMMA-GLOBULINS; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, SUBCUTANEOUS; LONGITUDINAL STUDIES; MALE; RETROSPECTIVE STUDIES; SPAIN;

EID: 60449099007     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1016/j.anpedi.2008.11.014     Document Type: Article

References (23)

1. Gardulf A. Subcutaneous administration of immunoglobulins - What are the advantages?. Clin Immunother 6 (1996) 108-116
2. Buckley R.H., and Schiff R.I. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 325 (1991) 110-117
3. Nicolay U., Kiessling P., Berger M., Gupta S., Yel L., Roifman C.M., et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 26 (2006) 65-72
4. ®. Mayo 2006.
5. Gardulf A., Nicolay U., Asensio O., Bernatowska E., Böck A., Carvalho B.C., et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - A prospective, multi-national study. J Clin Immunol 26 (2006) 177-185
6. Radinsky S., and Bonagura V.R. Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J Allergy Clin Immunol 112 (2003) 630-633
7. Chapel H.M., Spickett G.P., Ericson D., Engl W., Eibl M.M., and Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 20 (2000) 94-100
8. Gardulf A., Hammarström L., Gustafson R., Nyström T., Smith C.I.E., Gustafson R., et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 345 (1995) 365-369
9. Gustafson R., Gardulf A., Hansen S., Leibl H., Engl W., Lindén M., et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol 152 (2008) 274-279
10. ® [citado Mar 2008]. Disponible en: www.agemed.es.
11. Hansen S., Gustafson R., Smith C.I.E., and Gardulf A. Express subcutaneous IgG infusions: Decreased time of delivery with maintained safety. Clin Immunol 104 (2002) 237-241
12. Helbert M., and Farragher A. Subcutaneous immunoglobulin for patients with antibody deficiency. Br J Hosp Med 68 (2007) 206-210
13. Ochs H.D., Gupta S., Kiessling P., Nicolay U., and Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 26 (2006) 265-273
14. Kittner J.M., Grimbacher B., Wulff W., Jäger B., and Schmidt R.E. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol 26 (2006) 400-405
15. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 112 (2004) 1-7
16. Gaspar J., Gerritsen B., and Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child 79 (1998) 48-51
17. Abrahamsen T.G., Sandersen H., and Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 98 (1996) 1127-1131
18. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs 21 (2007) 105-116
19. Gardulf A., Borte M., Ochs H.D., and Nicolay U. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol 126 (2008) 81-88
20. Gardulf A., and Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 6 (2006) 434-442
21. Gardulf A., Nicolay U., Asensio O., Bernatowska E., Böck A., Costa-Carvalho B.T., et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 114 (2004) 936-942
22. Gardulf A., Möller G., and Jonsson E. A comparison of the patient-borne costs of theraphy with gamma-globulin given at the hospital or at home. Int J Technol Assess Health Care 11 (1995) 345-353
23. Hogy B., Keinecke H., and Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ 6 (2005) 24-29